134 related articles for article (PubMed ID: 16926162)
1. Insertion of an arginine residue into the transmembrane segments corrects protein misfolding.
Loo TW; Bartlett MC; Clarke DM
J Biol Chem; 2006 Oct; 281(40):29436-40. PubMed ID: 16926162
[TBL] [Abstract][Full Text] [Related]
2. Suppressor mutations in the transmembrane segments of P-glycoprotein promote maturation of processing mutants and disrupt a subset of drug-binding sites.
Loo TW; Bartlett MC; Clarke DM
J Biol Chem; 2007 Nov; 282(44):32043-52. PubMed ID: 17848563
[TBL] [Abstract][Full Text] [Related]
3. Introduction of the most common cystic fibrosis mutation (Delta F508) into human P-glycoprotein disrupts packing of the transmembrane segments.
Loo TW; Bartlett MC; Clarke DM
J Biol Chem; 2002 Aug; 277(31):27585-8. PubMed ID: 12070134
[TBL] [Abstract][Full Text] [Related]
4. Identification of residues in the drug translocation pathway of the human multidrug resistance P-glycoprotein by arginine mutagenesis.
Loo TW; Bartlett MC; Clarke DM
J Biol Chem; 2009 Sep; 284(36):24074-87. PubMed ID: 19581304
[TBL] [Abstract][Full Text] [Related]
5. Arginines in the first transmembrane segment promote maturation of a P-glycoprotein processing mutant by hydrogen bond interactions with tyrosines in transmembrane segment 11.
Loo TW; Bartlett MC; Clarke DM
J Biol Chem; 2008 Sep; 283(36):24860-70. PubMed ID: 18596043
[TBL] [Abstract][Full Text] [Related]
6. Processing mutations located throughout the human multidrug resistance P-glycoprotein disrupt interactions between the nucleotide binding domains.
Loo TW; Bartlett MC; Clarke DM
J Biol Chem; 2004 Sep; 279(37):38395-401. PubMed ID: 15247215
[TBL] [Abstract][Full Text] [Related]
7. Disulfide cross-linking analysis shows that transmembrane segments 5 and 8 of human P-glycoprotein are close together on the cytoplasmic side of the membrane.
Loo TW; Bartlett MC; Clarke DM
J Biol Chem; 2004 Feb; 279(9):7692-7. PubMed ID: 14670948
[TBL] [Abstract][Full Text] [Related]
8. Substrate-induced conformational changes in the transmembrane segments of human P-glycoprotein. Direct evidence for the substrate-induced fit mechanism for drug binding.
Loo TW; Bartlett MC; Clarke DM
J Biol Chem; 2003 Apr; 278(16):13603-6. PubMed ID: 12609990
[TBL] [Abstract][Full Text] [Related]
9. The DeltaF508 mutation disrupts packing of the transmembrane segments of the cystic fibrosis transmembrane conductance regulator.
Chen EY; Bartlett MC; Loo TW; Clarke DM
J Biol Chem; 2004 Sep; 279(38):39620-7. PubMed ID: 15272010
[TBL] [Abstract][Full Text] [Related]
10. Mapping the Binding Site of the Inhibitor Tariquidar That Stabilizes the First Transmembrane Domain of P-glycoprotein.
Loo TW; Clarke DM
J Biol Chem; 2015 Dec; 290(49):29389-401. PubMed ID: 26507655
[TBL] [Abstract][Full Text] [Related]
11. The W232R suppressor mutation promotes maturation of a truncation mutant lacking both nucleotide-binding domains and restores interdomain assembly and activity of P-glycoprotein processing mutants.
Loo TW; Bartlett MC; Clarke DM
Biochemistry; 2011 Feb; 50(5):672-85. PubMed ID: 21182301
[TBL] [Abstract][Full Text] [Related]
12. Membrane topology of P-glycoprotein as determined by epitope insertion: transmembrane organization of the N-terminal domain of mdr3.
Kast C; Canfield V; Levenson R; Gros P
Biochemistry; 1995 Apr; 34(13):4402-11. PubMed ID: 7535563
[TBL] [Abstract][Full Text] [Related]
13. Correctors promote maturation of cystic fibrosis transmembrane conductance regulator (CFTR)-processing mutants by binding to the protein.
Wang Y; Loo TW; Bartlett MC; Clarke DM
J Biol Chem; 2007 Nov; 282(46):33247-33251. PubMed ID: 17911111
[TBL] [Abstract][Full Text] [Related]
14. Processing mutations disrupt interactions between the nucleotide binding and transmembrane domains of P-glycoprotein and the cystic fibrosis transmembrane conductance regulator (CFTR).
Loo TW; Bartlett MC; Clarke DM
J Biol Chem; 2008 Oct; 283(42):28190-7. PubMed ID: 18708637
[TBL] [Abstract][Full Text] [Related]
15. Simultaneous binding of two different drugs in the binding pocket of the human multidrug resistance P-glycoprotein.
Loo TW; Bartlett MC; Clarke DM
J Biol Chem; 2003 Oct; 278(41):39706-10. PubMed ID: 12909621
[TBL] [Abstract][Full Text] [Related]
16. Val133 and Cys137 in transmembrane segment 2 are close to Arg935 and Gly939 in transmembrane segment 11 of human P-glycoprotein.
Loo TW; Bartlett MC; Clarke DM
J Biol Chem; 2004 Apr; 279(18):18232-8. PubMed ID: 14749322
[TBL] [Abstract][Full Text] [Related]
17. Mutations in intracellular loops 1 and 3 lead to misfolding of human P-glycoprotein (ABCB1) that can be rescued by cyclosporine A, which reduces its association with chaperone Hsp70.
Kapoor K; Bhatnagar J; Chufan EE; Ambudkar SV
J Biol Chem; 2013 Nov; 288(45):32622-32636. PubMed ID: 24064216
[TBL] [Abstract][Full Text] [Related]
18. Nucleotide binding, ATP hydrolysis, and mutation of the catalytic carboxylates of human P-glycoprotein cause distinct conformational changes in the transmembrane segments.
Loo TW; Bartlett MC; Clarke DM
Biochemistry; 2007 Aug; 46(32):9328-36. PubMed ID: 17636884
[TBL] [Abstract][Full Text] [Related]
19. Corrector VX-809 stabilizes the first transmembrane domain of CFTR.
Loo TW; Bartlett MC; Clarke DM
Biochem Pharmacol; 2013 Sep; 86(5):612-9. PubMed ID: 23835419
[TBL] [Abstract][Full Text] [Related]
20. Identification of residues in the drug-binding domain of human P-glycoprotein. Analysis of transmembrane segment 11 by cysteine-scanning mutagenesis and inhibition by dibromobimane.
Loo TW; Clarke DM
J Biol Chem; 1999 Dec; 274(50):35388-92. PubMed ID: 10585407
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
